{"id":"https://openalex.org/W155381746","doi":null,"title":"Alpha v integrin inhibitors and cancer therapy.","display_name":"Alpha v integrin inhibitors and cancer therapy.","publication_year":2003,"publication_date":"2003-06-01","ids":{"openalex":"https://openalex.org/W155381746","mag":"155381746","pmid":"https://pubmed.ncbi.nlm.nih.gov/12901232"},"language":"en","primary_location":{"id":"pmid:12901232","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12901232","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in investigational drugs (London, England : 2000)","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Gordon C Tucker","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405268767","display_name":"Institut de Recherches Internationales Servier (France)","ror":"https://ror.org/01zej3n42","country_code":"FR","type":"company","lineage":["https://openalex.org/I4405268767"]}],"countries":["FR"],"is_corresponding":true,"raw_author_name":"Gordon C Tucker","raw_affiliation_strings":["Institut de Recherches Servier, Cancer Research Division, 125 Chemin de Ronde, 78290 Croissy sur Seine, France. gordon.tucker@fr.netgrs.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institut de Recherches Servier, Cancer Research Division, 125 Chemin de Ronde, 78290 Croissy sur Seine, France. gordon.tucker@fr.netgrs.com","institution_ids":["https://openalex.org/I4405268767"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4405268767"],"apc_list":null,"apc_paid":null,"fwci":8.2076,"has_fulltext":false,"cited_by_count":108,"citation_normalized_percentile":{"value":0.98628258,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":97},"biblio":{"volume":"4","issue":"6","first_page":"722","last_page":"31"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10831","display_name":"Cell Adhesion Molecules Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2723","display_name":"Immunology and Allergy"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10831","display_name":"Cell Adhesion Molecules Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2723","display_name":"Immunology and Allergy"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10620","display_name":"Protease and Inhibitor Mechanisms","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T13326","display_name":"Biochemical and Structural Characterization","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cancer-therapy","display_name":"cancer therapy","score":0.7570000290870667},{"id":"https://openalex.org/keywords/cilengitide","display_name":"cilengitide","score":0.9990000128746033},{"id":"https://openalex.org/keywords/integrin-antagonists","display_name":"integrin antagonists","score":0.6800000071525574},{"id":"https://openalex.org/keywords/tumor-progression","display_name":"tumor progression","score":0.6729999780654907},{"id":"https://openalex.org/keywords/oral-bioavailability","display_name":"oral bioavailability","score":0.7450000047683716},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7369999885559082},{"id":"https://openalex.org/keywords/imaging-probes","display_name":"imaging agents","score":0.6480000019073486}],"concepts":[{"id":"https://openalex.org/C195687474","wikidata":"https://www.wikidata.org/wiki/Q409715","display_name":"Integrin","level":3,"score":0.6894144415855408},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5216965079307556},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.518844723701477},{"id":"https://openalex.org/C2779281246","wikidata":"https://www.wikidata.org/wiki/Q172847","display_name":"Peptide","level":2,"score":0.469698429107666},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.45921584963798523},{"id":"https://openalex.org/C64943373","wikidata":"https://www.wikidata.org/wiki/Q2651003","display_name":"Alpha (finance)","level":4,"score":0.4536442756652832},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4393683969974518},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.4178353250026703},{"id":"https://openalex.org/C70721500","wikidata":"https://www.wikidata.org/wiki/Q177005","display_name":"Computational biology","level":1,"score":0.3372572660446167},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.33226871490478516},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2678351402282715},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.22997909784317017},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.1706066131591797},{"id":"https://openalex.org/C2775944032","wikidata":"https://www.wikidata.org/wiki/Q22907659","display_name":"Patient satisfaction","level":2,"score":0.0},{"id":"https://openalex.org/C159110408","wikidata":"https://www.wikidata.org/wiki/Q121176","display_name":"Nursing","level":1,"score":0.0},{"id":"https://openalex.org/C49453240","wikidata":"https://www.wikidata.org/wiki/Q1592163","display_name":"Construct validity","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D016023","descriptor_name":"Integrins","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D016503","descriptor_name":"Drug Delivery Systems","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D016503","descriptor_name":"Drug Delivery Systems","qualifier_ui":"Q000639","qualifier_name":"trends","is_major_topic":false},{"descriptor_ui":"D039564","descriptor_name":"Integrin alphaV","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true}],"locations_count":2,"locations":[{"id":"pmid:12901232","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12901232","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in investigational drugs (London, England : 2000)","raw_type":"Journal Article"},{"id":"mag:155381746","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12901232","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2141134845","https://openalex.org/W2036968620","https://openalex.org/W2049195505","https://openalex.org/W1983518797","https://openalex.org/W1537203064","https://openalex.org/W1995855261","https://openalex.org/W2095829733","https://openalex.org/W2589223763","https://openalex.org/W4256315209","https://openalex.org/W7200254315"],"abstract_inverted_index":{"Recent":[0],"gene":[1],"disruption":[2],"experiments":[3],"have":[4,37],"suggested":[5],"that":[6],"targeting":[7,152],"the":[8,29,42,45,59,118,136,140],"alpha":[9,33,67,120],"v":[10,34,68],"integrins":[11],"(cell":[12],"surface":[13],"adhesion":[14],"and":[15,53,107,139],"signaling":[16],"receptors)":[17],"to":[18,41,66,93,101],"prevent":[19],"tumor":[20],"progression":[21],"can":[22],"result":[23],"in":[24,44,72,130],"different":[25],"outcomes":[26],"depending":[27],"on":[28],"strategy.":[30],"Nevertheless,":[31],"two":[32],"binding":[35],"antagonists":[36],"made":[38],"their":[39,143],"way":[40],"clinic":[43],"oncology":[46],"field;":[47],"both":[48],"Vitaxin,":[49],"a":[50,55],"humanized":[51],"antibody,":[52],"cilengitide,":[54],"cyclic":[56],"peptide":[57],"mimicking":[58],"RGD":[60],"ligand":[61],"recognition":[62],"peptidic":[63,82],"domain":[64],"common":[65],"integrin":[69],"ligands,":[70],"are":[71,91,128],"phase":[73],"II":[74],"clinical":[75],"trials.":[76],"This":[77,86],"year,":[78],"development":[79],"of":[80,113,135],"another":[81],"inhibitor":[83],"was":[84],"initiated.":[85],"review":[87,132],"questions":[88],"whether":[89],"companies":[90],"reluctant":[92],"propose":[94],"small":[95],"synthetic":[96],"heterocyclic":[97],"inhibitors":[98],"as":[99,145],"successors":[100],"peptide-derived":[102],"agents":[103,149],"with":[104],"better":[105],"pharmacokinetics":[106],"oral":[108,124],"bioavailability.":[109],"Is":[110],"this":[111,131],"class":[112],"compounds":[114,138],"immediably":[115],"flawed":[116],"like":[117],"platelet":[119],"IIb":[121],"beta":[122],"3":[123],"antagonists?":[125],"Tentative":[126],"answers":[127],"provided":[129],"following":[133],"description":[134],"lead":[137],"rationale":[141],"for":[142],"use":[144],"cancer":[146],"treatments,":[147],"imaging":[148],"or":[150],"drug":[151],"vectors.":[153]},"counts_by_year":[{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":4}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2016-06-24T00:00:00"}